Trials / Unknown
UnknownNCT02142790
Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Nanjing Luye Sike Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a open-label study in patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense paclitaxel liposome injection compared to 3-weekly regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paclitaxel liposome injection |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-06-01
- First posted
- 2014-05-20
- Last updated
- 2014-07-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02142790. Inclusion in this directory is not an endorsement.